For Healthcare Professionals Only.
As of February 2025, the Ministry of Health (MOH) has announced the inclusion of 20-valent pneumococcal conjugate vaccine (PCV20, marketed as Prevenar 20) in the National Adult Immunisation Schedule (NAIS). Effective from September 2025, PCV20 will be recommended for:
- All adults aged 65 years and older, and
- Adults aged 18 years and above with chronic conditions such as pulmonary or cardiovascular disease, diabetes, liver or kidney disease, immunocompromising conditions, anatomic or functional asplenia, cochlear implants, or cerebrospinal fluid leaks.
Subsidies under the VCDSS (Vaccination and Childhood Development Screening Subsidies) scheme will apply from September 2025, and MediSave use is expected to be available from mid-2026.
For full details, refer to MOH Circular No. 03/2025 on “Inclusion of Shingles Vaccine and Update to Pneumococcal Vaccine in the National Adult Immunisation Schedule” (10 February 2025).
Login to read more
